ENDPOINTS

FDA adcomm votes unanimously against Pfizer's prostate cancer drug combo

The FDA’s Oncologic Drugs Advisory Committee voted 8-0 against a new indication for Pfizer’s Talzenna in combination with Xtandi for first-line treatment of adults with non-homologous recombination repair mutated (non-HRRm) metastatic castration-resistant prostate cancer. ...

May 22, 2025 - 01:14
 0
FDA adcomm votes unanimously against Pfizer's prostate cancer drug combo
The FDA’s Oncologic Drugs Advisory Committee voted 8-0 against a new indication for Pfizer’s Talzenna in combination with Xtandi for first-line treatment of adults with non-homologous recombination repair mutated (non-HRRm) metastatic castration-resistant prostate cancer. ...
Read More

Tags:

Previous Article

The earth hath no fury like cyclones disrupted, new studies say

Next Article

In a marine heatwave, clownfish get small to get by

Related Posts

Cytokinetics gets an 'incremental' win for delayed heart drug

Cytokinetics gets an 'incremental' win for delayed hear...

May 13, 2025  0

It's been three months without a biotech IPO

It's been three months without a biotech IPO

May 16, 2025  0

Weight loss startup Calibrate replaces CEO in leadership shakeup 

Weight loss startup Calibrate replaces CEO in leadershi...

May 20, 2025  0